Point72 Europe (London) LLP Legend Biotech Corp Transaction History
Point72 Europe (London) LLP
- $1.1 Billion
- Q2 2024
A detailed history of Point72 Europe (London) LLP transactions in Legend Biotech Corp stock. As of the latest transaction made, Point72 Europe (London) LLP holds 22,245 shares of LEGN stock, worth $893,804. This represents 0.09% of its overall portfolio holdings.
Number of Shares
22,245Holding current value
$893,804% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding LEGN
# of Institutions
212Shares Held
77.9MCall Options Held
412KPut Options Held
387K-
Price T Rowe Associates Inc Baltimore, MD11.5MShares$462 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.51MShares$302 Million5.01% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.64MShares$267 Million7.6% of portfolio
-
Black Rock Inc. New York, NY5.72MShares$230 Million0.01% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.04MShares$202 Million1.16% of portfolio
About Legend Biotech Corp
- Ticker LEGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 167,403,008
- Market Cap $6.73B
- Description
- Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...